Please note also that the ABA Medical Necessity Guide may be updated and are, therefore, subject to change. Some plans exclude coverage for services or supplies that Aetna considers medically necessary. The member's benefit plan determines coverage. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Aetna) for a particular member. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusions or other benefit limitations applicable to this service or supply.
Members should discuss any matters related to their coverage or condition with their treating provider.Įach benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Treating providers are solely responsible for medical advice and treatment of members. The ABA Medical Necessity Guide does not constitute medical advice. The Applied Behavior Analysis (ABA) Medical Necessity Guide helps determine appropriate (medically necessary) levels and types of care for patients in need of evaluation and treatment for behavioral health conditions. doi:10.3389/ clicking on “I Accept”, I acknowledge and accept that: Pain in people with multiple sclerosis: associations with modifiable lifestyle factors, fatigue, depression, anxiety, and mental health quality of life. Marck CH, De Livera AM, Weiland TJ, et al. Complementary and alternative medicine usage by multiple sclerosis patients: results from a prospective clinical study. Kim S, Chang L, Weinstock-Guttman B, et al. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. Antiepileptic and antidepressive polypharmacy in patients with multiple sclerosis. Gabapentin.īeiske GA, Holmøy T, Beiske AG, Johannessen SI, Johannessen Landmark C. Co-occurring depression and pain in multiple sclerosis. doi:10.1002/3Īlschuler KN, Ehde DM, Jensen MP. Amitriptyline for neuropathic pain in adults. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. National Institute of Neurological Disorders and Stroke. Assessment andmeasurement of spasticity in MS: state of the evidence. A Survey of Severity and Distribution of Musculoskeletal Pain in Multiple Sclerosis Patients a Cross-Sectional Study. ShayestehAzar M, Kariminasab MH, Saravi MS, et al. Brisbane (AU): Codon Publications 2017 Nov 27. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis. Neuropathic pain in multiple sclerosis-current therapeutic intervention and future treatment perspectives. Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models. Characterizing chronic pain phenotypes in multiple sclerosis: a nationwide survey study. Kratz AL, Whibley D, Alschuler KN, et al.
0 kommentar(er)
